Compare ANVS & GLQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ANVS | GLQ |
|---|---|---|
| Founded | 2008 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.3M | 146.0M |
| IPO Year | 2019 | N/A |
| Metric | ANVS | GLQ |
|---|---|---|
| Price | $2.81 | $7.78 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $13.50 | N/A |
| AVG Volume (30 Days) | ★ 306.0K | 44.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.11% |
| EPS Growth | ★ 39.39 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.11 | $5.33 |
| 52 Week High | $5.50 | $8.38 |
| Indicator | ANVS | GLQ |
|---|---|---|
| Relative Strength Index (RSI) | 56.66 | 39.57 |
| Support Level | $2.29 | $7.48 |
| Resistance Level | $2.98 | $7.92 |
| Average True Range (ATR) | 0.20 | 0.12 |
| MACD | 0.03 | -0.05 |
| Stochastic Oscillator | 69.44 | 19.56 |
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
Clough Global Equity Fund is a closed-end management investment company. Its investment objective is to provide a high level of total return. The Fund invests in the equity, equity-related securities, and fixed-income securities in both U.S. and non-U.S. markets.